Presence of ? CTCAE grade  toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? CTCAE grade ) due to prior cancer therapy
Neuropathy, grade  or greater by NCI-CTCAE, v .
Patients ineligible for cisplatin based on any of the following criteria:\r\n* Estimated or calculated creatinine clearance >= ml/min but <  ml/min.\r\n* Grade  or above audiometric hearing loss (per CTCAE v.).\r\n* Grade  or above peripheral neuropathy (per CTCAE v.).
Subject has any peripheral neuropathy >= National Cancer Institute (NCI) CTCAE grade  at enrollment
Grade  to  peripheral neuropathy (NCI CTCAE v .).
CTCAE Grade >  neuropathy
Grade  or higher peripheral neuropathy or ataxia per NCI CTCAE
Patients with >= grade III or grade II with pain peripheral neuropathy (National Cancer Institute [NCI] CTCAE version [v.] . criteria)
Peripheral neuropathy > CTCAE grade 
Have Grade  or  peripheral neuropathy per NCI-CTCAE Version ..
CTCAE grade >=  peripheral neuropathy is NOT permitted
Evidence of peripheral neuropathy > grade  by NCI-CTCAE version .;
Otherwise, all toxicity at study entry < Grade  by NCI CTCAE v. (Patients with ? Grade  neuropathy are eligible).
Peripheral neuropathy National Cancer Institute (NCI) CTCAE >= grade  at baseline
Patients who have unresolved toxicity from all radiation, adjuvant/neoadjuvant chemotherapy, other targeted treatment including investigational treatment (exception of alopecia and ? Grade  peripheral neuropathy) according to NCI-CTCAE v. criteria
Subjects with neuropathy grade ? based on CTCAE v. at the time of study entry
CTCAE v Grade ? peripheral neuropathy
Neuropathy (?grade  CTCAE)
Motor peripheral neuropathy = grade  (per CTCAE v. .)
Grade  or higher peripheral neuropathy per NCI CTCAE
All prior treatment- related toxicities must be CTCAE (Version .) <=Grade  (except alopecia and peripheral neuropathy) at the time of treatment allocation [NCI-CTCAE, ].
Neuropathy >NCI-CTCAE Grade .
Neuropathy CTCAE grade > 
Neuropathy, grade  or greater by NCI-CTCAE, v. .
Presence of ? CTCAE grade  toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? CTCAE grade ) due to prior therapy.
Presence of NCI CTCAE ? grade  toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? NCI CTCAE grade ) due to prior cancer therapy
Presence of peripheral neuropathy ? CTCAE Grade 
Current NCI CTCAE (Version .) Grade >/=  peripheral neuropathy
Neuropathy, grade  or greater by NCI-CTCAE, v. .
CTCAE version . > grade  peripheral neuropathy
Has peripheral neuropathy ? Grade  (NCI-CTCAE)
Signs of peripheral neuropathy (PN) ? NCI CTCAE Grade .
Signs of peripheral neuropathy (PN) ? NCI CTCAE Grade .
Peripheral neuropathy CTCAE Grade ?
Grade  or higher peripheral neuropathy per NCI CTCAE
Any peripheral neuropathy ? NCI CTCAE Grade .
Symptomatic peripheral neuropathy grade ? NCI CTCAE v..
Peripheral neuropathy CTCAE v. Grade ? 
Peripheral neuropathy ? CTCAE Grade  at baseline.
Peripheral neuropathy ? CTCAE grade 
Subject has ? CTCAE v. Grade  neuropathy.
Clinical symptoms of peripheral neuropathy of grade  or grade  as measured by the National Cancer Institute (NCI)-CTCAE
Presence of neuropathy > Grade  per NCI CTCAE version .
